

## **Delcath Systems to Present at the 12th Annual LD Micro Main Event on December 10, 2019**

NEW YORK, Dec. 03, 2019 — Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that Dr. Jennifer Simpson, Ph.D., Chief Executive Officer and Ms. Barbra Keck, Chief Financial Officer, will present at the 12th Annual LD Micro Main Event investor conference at 1 p.m. PT (4 p.m. ET) on Tuesday, December 10, 2019.

The LD Micro Main Event will take place on December 10-12, 2019 in Los Angeles at the Luxe Sunset Bel Air Hotel. The investor conference will feature 275 companies and be attended by over 1,400 individuals.

Management will be available during the day on December 10 for one-on-one meetings. For more information about the conference or to schedule a one-on-one meeting with management, please contact [dcth@haydenir.com](mailto:dcth@haydenir.com).

### **About Delcath System, Inc.**

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product - Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) - is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have been enrolling a global Registration clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) called The FOCUS Trial and have initiated a global Phase 3 clinical trial for intrahepatic cholangiocarcinoma (ICC) called The ALIGN Trial. Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT) and has been used at major medical centers to treat a wide range of cancers of the liver. Since January 2019 CHEMOSAT is marketed under an exclusive licensing agreement with medac, a privately held multi-national pharmaceutical company headquartered in Germany and specializing in the treatment and diagnosis of oncological, urological and autoimmune diseases.

### **About LD Micro**

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.

What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide

intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.

For those interested in attending, please contact David Scher at [david@ldmicro.com](mailto:david@ldmicro.com) or visit [www.ldmicro.com](http://www.ldmicro.com) for more information.

**Contact:**

Delcath Investor Relations

Email: [investorrelations@delcath.com](mailto:investorrelations@delcath.com)

**Hayden IR**

James Carbonara

(646)-755-7412

[james@haydenir.com](mailto:james@haydenir.com)

Brett Maas

(646) 536-7331

[brett@haydenir.com](mailto:brett@haydenir.com)